Regeneron expects EYLEA HD demand growth in the low to mid-teens in Q3–Q4 2026 amid prefilled syringe push
Regeneron expects EYLEA HD demand to grow in the low to mid-teens percentage range, driven by the introduction of prefilled syringes between the third and fourth quarters of 2026.
Considering the current price, it may be advisable to approach the $700-710 range in a staggered manner, given the support level at $700 (recent correction low) and the resistance level at $750 (previous high), or to consider entering upon confirmation of a breakout above the $750 resistance level.
If it holds above the support level around $700, we will look to confirm a breakout above the previous resistance level of $750 and aim for a profit target of $765.0. However, if the $700.0 support level breaks or downward pressure increases, we will immediately manage risk at the stop-loss level of $700.0.
The RSI(14) is at 62.2, indicating a state just before entering overbought territory. The moving averages are misaligned, and the trading volume is 1.35 times the 20-day average. The recent 7-day volatility is +3.5%, suggesting that attention should be paid to box range volatility, and confirmation of the trend is needed at this time.
At the time of entry, the RSI was 62.2 and the moving averages were misaligned, leading to an expectation of box range volatility. A split entry was made at $700-710, with a trend-following strategy set for a breakout above $750. Initially, a conservative approach was considered based on a profit-taking target of $765.0; however, after entering on 2026-08-10, the price showed a strong increase in the candlestick data, reaching a closing price of $803.17, resulting in an actual return of 10.6%, significantly exceeding the predicted return of 2.5%. While keeping the possibility of a box breakout open and maintaining a trend-following perspective upon breaking resistance was valid, it is regrettable that the upside momentum driven by expectations of EYLEA HD demand growth was only conservatively limited, preventing the capture of the full extent of the actual surge.
In the upcoming trades, I will reflect an execution plan that not only responds to the simple range-bound trading but also flexibly adjusts the trend-following position when trading volume expands alongside positive news (growth in EYLEA HD demand and the push for pre-filled syringes). Particularly, even if the moving averages are misaligned, when the trading volume exceeds the 20-day average and strong momentum is confirmed, I will adopt an approach that prepares for an upside scenario rather than setting a tight target price.